Applications
CTC-Based Liquid Biopsy

Circulating tumor cells (CTCs) are the origin of distant cancer metastases, which are responsible for most cancer-related mortality. CTC count is associated with prognosis and response to therapy, and analysis of CTCs allows investigation of cancer cell biomarker expression and mutational status from a non-invasive liquid biopsy.

RareCyte® enables practical deployment of CTC-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single-cell isolation.


The RareCyte platform enables:

  • Monitoring CTC count and biomarker expression over time for clinical research
  • Custom assay and companion diagnostics development through our Pharma Programs 
  • Cancer-specific and Developer panels for your biomarkers
  • Examination of cancer mutations in single CTCs

Uniquely RareCyte

The RareCyte platform provides:

  • Reproducibility: End-to-end workflow designed for consistent results in multi-site deployment settings common to large clinical research studies
  • Flexibility: Three-day blood sample stability and bank-before-stain option enables practical clinical sample shipping, staining, and analysis pipelines
  • Sensitivity: Unbiased and highly sensitive target cell recovery with the AccuCyte® Sample Preparation System
  • Specificity: Up to six-channel fluorescence imaging with machine learning-enabled CTC detection protects against false positives
  • Validated panels: RarePlex® Staining Kits for research use designed for CTC identification and biomarker expression analysis
  • Retrieval: Gentle, single cell isolation for nucleic acid analysis

Image gallery of spike-in model CTCs surrounded by white blood cells on AccuCyte slides. Nuclei (magenta) / CK/EpCAM (green)

Contact us to learn more about our products for CTC-based liquid biopsy →



RareCyte panels for liquid biopsy analysis include markers used for CTC identification and biomarker exploration. CTCs are identified as nucleated cells that express CK/EpCAM but not CD45. The breast assay used the RarePlex HER2/ER CTC Panel Kit and the prostate assay used the ARv7 CTC Panel Kit and a Developer Kit for AR. With Developer technology, you can customize your panel with up to two of your own biomarkers.